GGrantIndex
← Leaderboards

David R Schubert

Salk Institute For Biological Studies

$11,912,596
Attributed
$13,635,099
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200519
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$13,635,099 · 10

By mechanism

R01$11,634,161 · 6
R21$2,000,938 · 4

Top collaborators

Most similar at Salk Institute For Biological Studies

Same institution · by research overlap

Others in their field

Top investigators on “Neurons

Research focus

NeuronsAlzheimer&AposAnimalsPathway InteractionsLeadPreventPharmaceutical PreparationsProteinsClinicToxic EffectMolecularAnimal ModelPathologyCell DeathTransgenic OrganismsNeurodegenerative DisordersBaseCell Culture TechniquesOxidative StressMolecular TargetWithdrawalAmyloidBehavioralBrain

Grant awards (34)

A Novel Drug Candidate for the Treatment of Huntington's Disease$240,500
R21 · FY2019 · NS
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$505,457
R01 · FY2018 · AG · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2018 · AG · contact PI
A Novel Drug Candidate for the Treatment of Huntington's Disease$288,600
R21 · FY2018 · NS
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2017 · AG · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2016 · AG · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$470,450
R01 · FY2015 · AG · contact PI
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets$485,000
R01 · FY2014 · AG · contact PI
Pan-Lipoxygenase Inhibitors for CNS Disease$375,373
R01 · FY2014 · AG · contact PI
Pan-Lipoxygenase Inhibitors for CNS Disease$354,726
R01 · FY2013 · AG · contact PI
Characterization of a Potent Neurogenic Compound$231,600
R21 · FY2013 · NS · contact PI
Pan-Lipoxygenase Inhibitors for CNS Disease$375,373
R01 · FY2012 · AG · contact PI
Characterization of a Potent Neurogenic Compound$288,000
R21 · FY2012 · NS · contact PI
Pan-Lipoxygenase Inhibitors for CNS Disease$375,373
R01 · FY2011 · AG · contact PI
A Novel Family of Neuroprotective Compounds for Stroke$819,669
R01 · FY2010 · NS · contact PI
Pan-Lipoxygenase Inhibitors for CNS Disease$390,525
R01 · FY2010 · AG · contact PI
In Vivo Efficacy of New Neuroprotective Drugs$234,383
R21 · FY2010 · NS · contact PI
A Novel Family of Neuroprotective Compounds for Stroke$817,346
R01 · FY2009 · NS · contact PI
In Vivo Efficacy of New Neuroprotective Drugs$284,100
R21 · FY2009 · NS · contact PI
Regulation of APP Degradation and ABeta Secretion$416,169
R01 · FY2008 · NS · contact PI
Regulation of APP Degradation and ABeta Secretion$25,000
R01 · FY2008 · NS · contact PI
Regulation of APP Degradation and ABeta Secretion$416,169
R01 · FY2007 · NS · contact PI
Regulation of APP Degradation and ABeta Secretion$428,598
R01 · FY2006 · NS · contact PI
Redox Sensitive Proteins in Aging and Neurodegeneration$374,331
R01 · FY2006 · AG · contact PI
Development and Testing of a Novel Neuroprotective Drug$214,299
R21 · FY2006 · NS · contact PI
Physiology of Nerve, Glial and Muscle Cell Lines$464,500
R01 · FY2005 · NS
Regulation of APP Degradation and ABeta Secretion$438,913
R01 · FY2005 · NS
Redox Sensitive Proteins in Aging and Neurodegeneration$383,325
R01 · FY2005 · AG
Development and Testing of a Novel Neuroprotective Drug$219,456
R21 · FY2005 · NS
Physiology of Nerve, Glial and Muscle Cell Lines$464,500
R01 · FY2004 · NS
Redox Sensitive Proteins in Aging and Neurodegeneration$404,864
R01 · FY2004 · AG
Physiology of Nerve, Glial and Muscle Cell Lines$464,500
R01 · FY2003 · NS
Physiology of Nerve, Glial and Muscle Cell Lines$464,500
R01 · FY2002 · NS
Physiology of Nerve, Glial and Muscle Cell Lines$464,500
R01 · FY2001 · NS